Very small blood clot risk after first AstraZeneca COVID dose, suggests Study
Study found no risk of major arterial and venous thrombotic events in those aged 70 or above with either of the vaccines.
New Delhi: A large study into rare blood clots linked with AstraZeneca's COVID-19 vaccine found between just one and three cases per million, and only after the first dose, shedding fresh light on the side-effects from the shot.
AstraZeneca said in a statement the study confirmed what is already known about "extremely rare blood disorders following vaccination."
"The risk of developing this very rare condition remains substantially higher after COVID-19," it added.
Last year, a study led and funded by AstraZeneca found its vaccine carried a small additional risk of thrombosis with thrombocytopenia syndrome after the first dose but none after the second.
AstraZeneca-Oxford's ChAdOx1 nCoV-19 shot, sold under the brands Vaxzevria and Covishield with more than 2.6 billion doses supplied globally as of February, remains a key weapon against the pandemic in middle-income countries.
A second peer-reviewed British study also released on Tuesday found the risk of cerebral venous sinus thrombosis (CVST) in the four weeks after receiving the AstraZeneca-Oxford shot was roughly twice as high as before vaccination, but it still implied only one in four million people could have the side-effect.
The study assessed data for more than 11 million people in England, Scotland and Wales, spanning nearly seven months from December 2020 to June 2021.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.